The identification of microRNA biomarkers in the cerebrospinal fluid may become an important method for the diagnosis of primary central nervous system disorders.

Researchers have identified and quantified microRNAs in cerebrospinal fluid samples taken from patients with primary central nervous system lymphomas and as well as patients with a variety of neurologic disorders, including inflammatory disorders1.

The identification of microRNA biomarkers in CSF was first reported back in 20082.

1.     Baraniskin A, Kuhnhenn J, Schlegel U, Chan A, Deckert M, Gold R, Maghnouj A, Zöllner H, Reinacher-Schick A, Schmiegel W, Hahn SA, Schroers R. (2011) Identification of microRNAs in the cerebrospinal fluid as marker for primary diffuse large B-cell lymphoma of the central nervous system. Blood [Epub ahead of print]. [abstract]

2.     Cogswell JP, Ward J, Taylor IA, Waters M, Shi Y, Cannon B, Kelnar K, Kemppainen J, Brown D, Chen C, Prinjha RK, Richardson JC, Saunders AM, Roses AD, Richards CA. (2008) Identification of miRNA changes in Alzheimer’s disease brain and CSF yields putative biomarkers and insights into disease pathways. J Alzheimers Dis 14(1), 27-41. [abstract]

Incoming search terms for this article:


Asuragen Reports Notice of Allowance from USPTO Related to the Diagnostic Application of an Important Cancer-Related miRNA

AUSTIN, Texas–(BUSINESS WIRE)–Asuragen, Inc., a leader in the development of molecular diagnostics, announced today that it had received a Notice of Allowance from the United States Patent and Trademark Office (“USPTO”) for claims related to the use of mir-205 as a diagnostic in lung cancer. Human mir-205 has been identified as being highly expressed in lung cancer when compared with its expression in normal lung tissue, and, as a result, is an excellent marker for use as a diagnostic for lung cancer. Asuragen has a broad IP portfolio with over 69 issued and pending patents related to miRNA including some of the earliest functional diagnostic applications for a number of key miRNAs associated with oncology diseases.

 “miRNAs are a category of biomarkers whose importance is increasingly being recognized as is evidenced by the explosion in the number of publications regarding miRNAs. We started working on miRNAs in 2002 prior to our selling Ambion and are pleased that the first, of what is a large portfolio of pending patents, are starting to issue,” said Matt Winkler, CEO and CSO of Asuragen. “This allowance from the USPTO highlights the early work we did in the newly emerging field of microRNAs and it supports our continuing development work towards novel miRNA-based molecular diagnostics for cancer.” This follows closely on the heels of a Notice of Allowance received by Yale University for its let7 patent portfolio for which Asuragen is the exclusive licensee in the fields of diagnostics.

(read the entire release… )


miRNAs’ Therapeutic Potential

by Chris on March 31, 2010

in News

10-06GEN_Mar15_01a-31Scientists Scrutinize Promising Molecules as Potential Drug Targets and Biomarkers

Genetic Engineering News – Patricia F. Dimond, Ph.D.

MicroRNAs (miRNAs) finely regulate gene expression and play an important role in various cellular processes, including cell growth, differentiation, proliferation, and apoptosis. To date, more than 5,000 of these endogenous, noncoding single-stranded RNAs have been identified. miRNAs act through binding to complementary mRNA sequences, thereby preventing their translation into protein or accelerating mRNA breakdown. Investigators are working on exploiting these molecules for experimental and potential therapeutic applications. (read more)


Plos-One---2009---ExpressioResearchers at the University of Malaya, Kuala Lumpur and the National University of Singapore demonstrate that peripheral blood miRNAs and their profiles can be developed as biomarkers in diagnosis and prognosis of cerebral ischaemic stroke. MicroRNA microarrays were utilized to detect dysregulated miRNAs even after several months from the onset of stroke in what is usually regarded as neurologically stable patients.

Tan KS, Armugam A, Sepramaniam S, Lim KY, Setyowati KD, Wang CW, Jeyaseelan K.  (2009) Expression profile of MicroRNAs in young stroke patients. PLoS One 4(11), e7689.  [article]


Heart disease and cancer represent the number one and number two killer diseases in developed countries. Identifying biomarkers to detect these and other diseases at early stages remains an important research goal and researchers are scrambling for ways to identify contributing factors to the pathogenesis of diseased cells in the body.  In recent years, research has turned to the study of microRNA (miRNA) as possible biomarkers due to their extensive role in biological processes and cell functionality in normal vs. diseased cells.  Microarrays combined with quantitative real-time PCR (qRT-PCR) validation are proving to be valuable tools for miRNA expression profiling and are predicted to play a crucial role in biomarker discovery and detection.  [click to continue…]

Incoming search terms for this article: